Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2022-08-23 Capital/Financing Update
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Prescient Therapeutics Launches Share Purchase Plan 5 pages 850.9KB
Capital/Financing Update Classification · 95% confidence The document is an announcement by Prescient Therapeutics about launching a Share Purchase Plan (SPP) to raise $8.0 million. It details the terms of the SPP, including the share price, discount, record date, timetable, and use of funds. It also includes information about a shareholder briefing and contact details. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is focused on capital raising activity through a share issue to existing shareholders. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length is over 13,000 characters, so it is not a brief announcement or a report publication announcement. Therefore, the correct classification is CAP with high confidence.
2022-08-23 English
Share Purchase Plan Booklet 9 pages 589.5KB
Capital/Financing Update Classification · 95% confidence The document is a detailed letter and explanatory material from the board of Prescient Therapeutics Limited regarding a Share Purchase Plan (SPP). It includes offer details, terms, risks, and instructions for shareholders to participate in purchasing additional shares. The content focuses on capital raising through a share issue, including pricing, record dates, closing dates, and use of funds. There is no financial statement or earnings data, nor is it a report of voting results or management changes. The document is clearly an announcement and explanatory material related to a capital raising activity via a share purchase plan. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to the explicit focus on share issuance and capital raising terms.
2022-08-23 English
Proposed issue of securities - PTX 7 pages 31.6KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Prescient Therapeutics Limited regarding a proposed issue of securities under a securities purchase plan. It details the number of securities to be issued, offer price, conditions, timetable, fees, and purpose of the capital raised. The content focuses on fundraising and capital structure changes rather than financial results or management commentary. There is no indication of it being a full financial report, earnings release, or regulatory certification. The document fits the definition of a Capital/Financing Update, which covers company fundraising and capital structure changes.
2022-08-23 English
Appendix 4E and 2022 Annual Report 53 pages 2.1MB
Annual Report Classification · 100% confidence The document is titled 'Prescient Therapeutics Limited Appendix 4E Preliminary final report' and covers the financial year ended 30 June 2022. It includes detailed financial results, company details, directors' report, auditor's report, consolidated financial statements, and notes. The content includes comprehensive financial performance data, financial position, directors' report, and auditor's opinion, which are typical components of an Annual Report. The document also explicitly states that the Annual Report for the year ended 30 June 2022 is attached, and the text includes the full Annual Report contents and sections. The length of the document (15,000 characters) and the detailed financial data confirm it is the full Annual Report, not just an announcement or summary. Therefore, the correct classification is Annual Report (10-K). FY 2022
2022-08-22 English
Appendix 4G and Corporate Governance Statement 25 pages 1.5MB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a form used by Australian listed entities to confirm compliance with corporate governance disclosure requirements. The document includes a checklist of governance principles and recommendations, indicating which have been followed and where disclosures can be found, often pointing to the corporate governance statement on the company's website or annual report. It explicitly states that Appendix 4G is not a substitute for the corporate governance statement but serves as a verification tool for compliance with Listing Rule 4.10.3. The document does not contain financial statements or detailed financial analysis but is a regulatory compliance filing related to governance disclosures. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2022-08-22 English
PTX Presentation 59 pages 2.6MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Prescient Therapeutics Limited, focusing on their corporate snapshot, investment highlights, pipeline of therapies, clinical trial updates, and scientific background on CAR-T therapies. It contains forward-looking statements, clinical trial data, and strategic information about the company's drug development programs. There is no indication that this is an official annual report, audit report, earnings release, or regulatory filing. The content is educational and promotional, aimed at investors and stakeholders to provide a comprehensive overview of the company's business and prospects. This matches the characteristics of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification rather than a brief announcement or a regulatory filing.
2022-08-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.